Position in EXEL
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$14,792,881
+$8,660,469 QoQ
Shares Held
271,878
+90.2% QoQ
Ownership
0.110%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
#111
of 756 holders
Holding Since
Sep 2022
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Clark Capital Management Group, Inc. holds $136,817,304 across 5 Biotechnology names. EXEL ranks #3 (10.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
|
1,663,003 | $93,244,578 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
231,956 | $18,155,196 | |
| 3 | EXEL |
Exelixis, Inc.
This page
|
271,878 | $14,792,881 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
|
32,948 | $10,414,533 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
423 | $210,116 |
All Filings in EXEL
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $14,792,881 | 271,878 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $6,132,412 | 142,980 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $13,634,724 | 311,082 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $12,043,782 | 291,617 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $11,251,023 | 255,241 | Shares | Sole | 2025-08-14 | |
| 2024-03-31 | $2,113,251 | 89,054 | Shares | Sole | 2024-05-15 | |
| 2022-12-31 | $2,457,568 | 153,215 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $1,209,774 | 77,154 | Shares | Sole | 2022-11-14 | |
| No filing history on record for this holder in this stock. | ||||||